597 related articles for article (PubMed ID: 16322137)
1. The histrelin implant: a novel treatment for central precocious puberty.
Hirsch HJ; Gillis D; Strich D; Chertin B; Farkas A; Lindenberg T; Gelber H; Spitz IM
Pediatrics; 2005 Dec; 116(6):e798-802. PubMed ID: 16322137
[TBL] [Abstract][Full Text] [Related]
2. Time to menarche and final height after histrelin implant treatment for central precocious puberty.
Gillis D; Karavani G; Hirsch HJ; Strich D
J Pediatr; 2013 Aug; 163(2):532-6. PubMed ID: 23485026
[TBL] [Abstract][Full Text] [Related]
3. Free alpha-subunit is the most sensitive marker of gonadotropin recovery after treatment of central precocious puberty with the histrelin implant.
Hirsch HJ; Lahlou N; Gillis D; Strich D; Rosenberg-Hagen B; Chertin B; Farkas A; Hartman H; Spitz IM
J Clin Endocrinol Metab; 2010 Jun; 95(6):2841-4. PubMed ID: 20339028
[TBL] [Abstract][Full Text] [Related]
4. Long-term treatment of central precocious puberty with a long-acting analogue of luteinizing hormone release hormone (D-Tryp6-GnRH) in monthly injections. Its possible use in normal puberty.
Marcondes JA; Abujamra AC; Minanni SL; Mendonca BB; Nery M; Lerario AC; Pereira MA; Abelin N; Wajchenberg BL
Horm Metab Res; 1993 Feb; 25(2):105-9. PubMed ID: 8458605
[TBL] [Abstract][Full Text] [Related]
5. An implant releasing the gonadotropin hormone-releasing hormone agonist histrelin maintains medical castration for up to 30 months in metastatic prostate cancer.
Chertin B; Spitz IM; Lindenberg T; Algur N; Zer T; Kuzma P; Young AJ; Catane R; Farkas A
J Urol; 2000 Mar; 163(3):838-44. PubMed ID: 10687989
[TBL] [Abstract][Full Text] [Related]
6. Growth outcome during GnRH agonist treatments for slowly progressive central precocious puberty.
Massart F; Federico G; Harrell JC; Saggese G
Neuroendocrinology; 2009; 90(3):307-14. PubMed ID: 19641297
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of histrelin subdermal implant in children with central precocious puberty: a multicenter trial.
Eugster EA; Clarke W; Kletter GB; Lee PA; Neely EK; Reiter EO; Saenger P; Shulman D; Silverman L; Flood L; Gray W; Tierney D
J Clin Endocrinol Metab; 2007 May; 92(5):1697-704. PubMed ID: 17327379
[TBL] [Abstract][Full Text] [Related]
8. Adequacy of a single unstimulated luteinizing hormone level to diagnose central precocious puberty in girls.
Houk CP; Kunselman AR; Lee PA
Pediatrics; 2009 Jun; 123(6):e1059-63. PubMed ID: 19482738
[TBL] [Abstract][Full Text] [Related]
9. Basal luteinizing hormone/follicle stimulating hormone ratio in diagnosis of central precocious puberty.
Supornsilchai V; Hiranrat P; Wacharasindhu S; Srivuthana S; Aroonparkmongkol S
J Med Assoc Thai; 2003 Jun; 86 Suppl 2():S145-51. PubMed ID: 12929982
[TBL] [Abstract][Full Text] [Related]
10. The relationship between luteinizing hormone and estradiol secretion in female precocious puberty: evaluation by sensitive gonadotropin assays and the leuprolide stimulation test.
Garibaldi LR; Aceto T; Weber C; Pang S
J Clin Endocrinol Metab; 1993 Apr; 76(4):851-6. PubMed ID: 8473395
[TBL] [Abstract][Full Text] [Related]
11. Subcutaneous gonadotropin-releasing hormone agonist (triptorelin) test for diagnosing precocious puberty.
Poomthavorn P; Khlairit P; Mahachoklertwattana P
Horm Res; 2009; 72(2):114-9. PubMed ID: 19690429
[TBL] [Abstract][Full Text] [Related]
12. Growth, bone maturation and height prediction after three years of therapy with the slow release GnRH-agonist Decapeptyl-Depot in children with central precocious puberty.
Hümmelink R; Oostdijk W; Partsch CJ; Odink RJ; Drop SL; Sippell WG
Horm Metab Res; 1992 Mar; 24(3):122-6. PubMed ID: 1533604
[TBL] [Abstract][Full Text] [Related]
13. Bone mineral content in girls with precocious puberty treated with gonadotropin-releasing hormone analog.
Verrotti A; Chiarelli F; Montanaro AF; Morgese G
Gynecol Endocrinol; 1995 Dec; 9(4):277-81. PubMed ID: 8629454
[TBL] [Abstract][Full Text] [Related]
14. Long-Term Continuous Suppression With Once-Yearly Histrelin Subcutaneous Implants for the Treatment of Central Precocious Puberty: A Final Report of a Phase 3 Multicenter Trial.
Silverman LA; Neely EK; Kletter GB; Lewis K; Chitra S; Terleckyj O; Eugster EA
J Clin Endocrinol Metab; 2015 Jun; 100(6):2354-63. PubMed ID: 25803268
[TBL] [Abstract][Full Text] [Related]
15. Reproductive axis after discontinuation of gonadotropin-releasing hormone analog treatment of girls with precocious puberty: long term follow-up comparing girls with hypothalamic hamartoma to those with idiopathic precocious puberty.
Feuillan PP; Jones JV; Barnes K; Oerter-Klein K; Cutler GB
J Clin Endocrinol Metab; 1999 Jan; 84(1):44-9. PubMed ID: 9920060
[TBL] [Abstract][Full Text] [Related]
16. Prolactin secretion before, during, and after chronic gonadotropin-releasing hormone agonist treatments in children.
Massart F; Parrino R; Placidi G; Massai G; Federico G; Saggese G
Fertil Steril; 2005 Sep; 84(3):719-24. PubMed ID: 16169408
[TBL] [Abstract][Full Text] [Related]
17. Gonadotropin-releasing hormone testing in premature thelarche.
Choubtum L; Mahachoklertwattana P; Sriphrapradang A; Preeyasombat C
J Med Assoc Thai; 1999 Nov; 82 Suppl 1():S33-8. PubMed ID: 10730515
[TBL] [Abstract][Full Text] [Related]
18. [Impact of gonadotropin-releasing hormone analogs treatment on final height in girls with central precocious puberty].
Chen SK; Fan X; Tang Q
Zhongguo Dang Dai Er Ke Za Zhi; 2009 May; 11(5):374-6. PubMed ID: 19470261
[TBL] [Abstract][Full Text] [Related]
19. Insulin-like growth factor-I and IGF binding protein-3 remain high after GnRH analogue therapy in girls with central precocious puberty.
Kanety H; Karasik A; Pariente C; Kauschansky A
Clin Endocrinol (Oxf); 1996 Jul; 45(1):7-12. PubMed ID: 8796132
[TBL] [Abstract][Full Text] [Related]
20. Adult height in girls with central precocious puberty treated with gonadotropin-releasing hormone analogues and growth hormone.
Pasquino AM; Pucarelli I; Segni M; Matrunola M; Cerroni F
J Clin Endocrinol Metab; 1999 Feb; 84(2):449-52. PubMed ID: 10022399
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
